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LETTERS
Powassan Virus  
Encephalitis,  
Minnesota, USA
To the Editor: Birge and Son-
nesyn report the first death of a Min-
nesota resident caused by Powassan 
virus (POWV) (1). However, they 
provide an inaccurate description of 
several critical diagnostic and surveil-
lance issues concerning POWV.
The 17 POWV infections detect-
ed in Minnesota residents from 2008 
through 2011 (6 cases were identi-
fied through 2010, not 8 as reported 
by Birge and Sonnesyn) (Minnesota 
Department of Health [MDH], unpub. 
data) were found through enhanced 
surveillance. Health alerts to Min-
nesota medical providers described 
POWV as a possible etiologic agent 
for viral meningitis and encephalitis. 
Providers consulted with MDH on 
suspected cases and submitted serum 
and cerebrospinal fluid specimens to 
MDH. MDH conducted serologic test-
ing for endemic arboviruses (includ-
ing POWV) and reverse transcription 
PCR (RT-PCR) for flaviviruses and 
POWV. MDH would not have de-
tected any POWV infections without 
enhanced surveillance. Limited field 
studies also identified POWV-infected 
ticks in 4 Minnesota counties (not 2 as 
reported [1]) (MDH, unpub. data).
Commercial laboratories do not 
provide testing for POWV, and only 
a few state health department labo-
ratories and the Centers for Disease 
Control and Prevention offer testing. 
Serologic testing (enzyme immuno-
assay with plaque-reduction neutral-
ization testing confirmation) is pre-
ferred (2) because POWV RT-PCRs 
are not validated, and the short vire-
mic periods of flaviviruses limit their 
usefulness (3).
Few POWV infections are identi-
fied by lineage (prototype vs. deer tick 
virus); Minnesota’s first case in 2008 
was identified as a deer tick virus in-
fection, but the lineage was unknown 
for the other 16 cases. However, many 
case-patients had likely exposure to 
Ixodes scapularis ticks (blacklegged 
ticks), the tick species associated with 
deer tick virus transmission, and virus-
es from all POWV-positive tick pools 
were confirmed as deer tick virus by 
sequencing. The distribution of the 2 
lineages in North America is poorly 
understood, and most cases likely go 
undetected without specific POWV 
surveillance efforts.
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Hepatitis E  
Virus and  
Porcine-derived 
Heparin
To the Editor: Cases of spo-
radic, locally acquired hepatitis E 
have been increasingly identified in 
industrialized countries over the last 
few years (1). In this setting, hepatitis 
E is thought to be a zoonotic infec-
tion, with pigs as the primary host. 
Consumption of uncooked or lightly 
cooked pork meat products is thought 
to be a key route of infection, but oth-
er routes of transmission have been 
documented (2). For example, there 
have been several iatrogenic cases 
after transfusion of hepatitis E virus 
(HEV)–contaminated blood products 
(3) and transplantation of an HEV-
infected donor liver (4). However, in 
most cases the source and route of in-
fection are uncertain.
In May 2011, a 42-year-old 
woman sought care at the Royal 
Cornwall Hospital in Truro, United 
Kingdom, for a 1-week history of 
malaise, diarrhea, nausea, and vom-
iting. Physical examination results 
were normal. Her liver function test 
results, however, indicated hepatitis: 
alanine aminotransferase 2,785 IU/L 
(reference range 10–36 IU/L), alka-
line phosphatase 319 IU/L (reference 
range 30–130 IU/L), and bilirubin 30 
µmol/L (reference range <21 µmol/L). 
HEV IgM and IgG serologic test re-
sults for the patient were positive, 
and HEV genotype 3 was identified 
in her blood by reverse transcription 
PCR and sequencing. Other causes 
of viral hepatitis and hepatocellular 
jaundice, including hepatitis viruses 
A, B, and C; Epstein-Barr virus; and 
autoimmune hepatitis, were excluded 
by testing. As with most immunocom-
petent persons with HEV, the patient 
made an uneventful clinical recovery 
after 12 weeks, and her liver func-









The source and route of infection 
in this case was uncertain. A detailed 
in-person assessment of potential 
risk factors was undertaken with the 
patient. She had not traveled outside 
the United Kingdom in the previous 3 
months. She rarely ate pork products 
(well cooked bacon only); ate no shell-
fish; and had no workplace, domestic, 
or recreational exposure to pigs or 
their effluent. However, 4 weeks be-
fore symptom onset, the patient had 
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Sanofi‡      
 Clexhane/enoxaparin Injection H2O    
 ILA01   20	mg/0.2	mL 6,000 0.0006 
 34751   40	mg/0.4	mL 4,000 0.0009 
 OLC56   80	mg/0.8	mL 8,000 0.0005 
 ILA53   60	mg/0.6	mL 6,000 0.0006 
 OLC07   100	mg/	mL 10,000 0.0004 
 12255   120	mg/0.8	mL 12,000 0.0003 
Pfizer§      
 Fragmin/dalteparin	sodium Injection H2O	pH	adjusted	with	
HCl	or	NaOH 
   
 12339A01   5,000	IU/0.2	mL 15,000 0.0002 
 12338A01   5,000	IU/0.2	mL 15,000 0.0002 
 12327B01   5,000	IU/0.2	mL 15,000 0.0002 
 12257A01   5,000	IU/0.2	mL 15,000 0.0002 
 12444A01   5,000	IU/0.2	mL 10,000 0.0004 
 12122C01   7,500	IU/0.3	mL 7,500 0.0005 
 74774D51   10,000	IU/0.4	mL 10,000 0.0004 
 74871B51   12,500	IU/0.5	mL 25,000 0.0001 
 74779G51   12,500	IU/0.5	mL 12,500 0.0003 
 74871B51   12,500	IU/0.5 mL 12,500 0.0003 
 74743C52   15,000	IU/0.6	mL 30,000 0.0001 
 74755A51   15,000	IU/0.6	mL 30,000 0.0001 
 74832A52   15,000	IU/0.6	mL 15,000 0.0002 
 74832A01   15,000	IU/0.6	mL 15,000 0.0002 
 X08580 ¶ ¶ 100,000	IU/4	mL 100,000 0.00004 
Wockhart#      
 Monoparin Injection H2O	pH	adjusted	with	
HCl	or	NaOH 
   
  PK40319   1,000	IU/mL 20,000 0.0002 
  3090   1,000	IU/mL 10,000 0.0004 
 Hepsal Flushing NaCl,	H2O,	HCl,	and	
NaOH 
   
  5000090   10	IU/mL 120 0.03 
  91180   50	IU/mL 50 0.07 
  1069   200	IU/mL 200 0.02 









   
  DD7314   100	IU/mL 200 0.02 
  CC4338   100	IU/mL 200 0.02 
Celgene††,       
 Refludan/Lepirudin, 25561611A‡‡ Powder	used	for	
solution	for	
injection/infusion 
Mannitol,	NaOH,	and	H2O 12.5	mg/mL NA NA 
Total	quantity	tested NA NA NA 404,270 0.000009 
*NA,	not	applicable. 
†The 95% upper confidence limit of the probability of a virus-positive	result	per	IU	was	calculated	on	the	basis	of	the	quantity	tested	for	each	batch.	This	
was	estimated,	assuming	perfect	detection	of	a	Poisson	process,	by	using	Fisher	exact	test.	For	the pooled	result,	the	upper	95%	estimate	is	1	per	
100,000	IU. 










acute appendicitis for which she un-
derwent an uneventful laparoscopic 
appendectomy and was hospitalized 
for 2 days. During hospitalization 
she received no blood products, but, 
as prophylaxis for thromboembolic 
disease, she received 2 doses (5,000 
IU each) of low–molecular weight 
heparin (Fragmin [dalteparin sodium]; 
Pfizer, Sandwich, UK) by subcutane-
ous injection. All heparins used in Eu-
rope and North America are isolated 
from porcine intestinal mucosa (5). 
The exact purification methods used 
by heparin manufacturers are deemed 
commercially sensitive and not in the 
public domain, so it is impossible to 
evaluate whether the isolation process 
would be sufficient to remove or in-
activate any contaminating HEV. The 
virus is known to be acid and alkaline 
stable; heat sensitivity varies, depend-
ing on strain and heating conditions, 
although heating at 60°C for 1 hour 
is generally sufficient to achieve 96% 
inactivation (6). To our knowledge, no 
investigation has determined whether 
clinical-grade heparin could contain 
viral contaminants. Thus, we hypoth-
esized that the heparin the patient re-
ceived might have been the source of 
her HEV infection.
To examine this possibility, we 
screened multiple batches of hospital 
pharmacy–grade heparin for the pres-
ence of HEV, including batches of 
dalteparin sodium that were in use at 
the hospital when the patient received 
treatment for appendicitis. Before 
testing, the samples were ultracentri-
fuged to concentrate any contaminat-
ing virus and enable the removal of 
excipients, which could inhibit the as-
say. We tested samples by quantitative 
reverse transcription PCR (7) in paral-
lel with positive World Health Orga-
nization HEV RNA standard spiked 
controls, which showed the limit of 
detection (LOD) to be 500 IU/mL, re-
gardless of the heparin’s excipient or 
concentration. This LOD is within the 
range used by collaborating laborato-
ries in the establishment of the World 
Health Organization HEV RNA 
standard (http://whqlibdoc.who.int/
hq/2011/WHO_BS_2011.2175_eng.
pdf). In addition, we tested the hepa-
rin samples for porcine circovirus 2 
(PCV2), an identified adventitious 
agent of several rotavirus vaccines (8) 
and porcine parvovirus (PPV) (9), a 
known contaminate of porcine clot-
ting factor hyate:C (10). Although 
samples were tested in parallel with 
PCV2- and PPV- positive spiked con-
trols, we were unable to calculate the 
LOD for these assays because interna-
tional standards are not available for 
these viruses.
All samples tested negative for 
HEV, PCV2, and PPV (Table), which 
would indicate the patient’s source 
of HEV infection is unlikely to have 
been the heparin. However, we cannot 
rule out low-level viral contamination 
below the sensitivity of the assay. We 
also cannot exclude that the negative 
test results were related to the Pois-
son effect. Given that all samples ana-
lyzed were negative for all 3 viruses 
tested, it seems likely that the heparin 
manufacturing process is sufficient to 
remove viral contaminants. However, 
this may not necessarily be the case 
for other porcine-derived products, 
such as porcine insulin, factor VIII C, 
pancreatin, and poractant alfa. Further 
investigation is warranted to exclude 
these products as potential sources of 
HEV infection.
Acknowledgment
We thank the Chief Scientist Office 
of Scotland who funded this work under 
project ETM/32.
C. Crossan, L. Scobie,  
J. Godwin, J.G. Hunter,  
T. Hawkes, and H.R. Dalton 
Author	 affiliations:	 Glasgow	 Caledonian	
University,	 Glasgow,	 Scotland,	 UK	 (C.	






  1.  Kamar N, Bendall R, Abravanel F, Xia 
N, Ijaz S, Izopet J, et al. Hepatitis E. 
Lancet. 2012;379:2477–88. http://dx.doi.
org/10.1016/S0140-6736(11)61849-7
  2.  Scobie L, Dalton HR. Hepatitis E: 
source and route of infection, clinical 
manifestations and new developments. J 
Viral Hepat. 2013;20:1–11. http://dx.doi.
org/10.1111/jvh.12024 
  3.  Colson P, Coze C, Gallian P, Henry M, De 
Micco P, Tamalet C. Transfusion-associat-
ed hepatitis E, France. Emerg Infect Dis. 
2007;13:648–9. http://dx.doi.org/10.3201/
eid1304.061387
  4.  Schlosser B, Stein A, Neuhaus R, Paul 
S, Ramez B, Kruger DH, et al. Liver 
transplant from a donor with occult 
HEV infection induced chronic hepa-
titis and cirrhosis in the recipient. J 
Hepatol. 2012;56:500–2. http://dx.doi.
org/10.1016/j.jhep.2011.06.021
  5.  Alban S. The ‘precautionary principle’ 
as a guide for future drug development. 
Eur J Clin Invest. 2005;35(Suppl 1):33–
44. http://dx.doi.org/10.1111/j.0960-13 
5X.2005.01455.x
  6.  Emerson SU, Arankalle VA, Purcell RH. 
Thermal stability of hepatitis E virus. J 
Infect Dis. 2005;192:930–3. http://dx.doi.
org/10.1086/432488
  7.  Jothikumar N, Cromeans TL, Robertson 
BH, Meng XJ, Hill VR. A broadly reac-
tive one-step real-time RT-PCR assay 
for the rapid and sensitive detection of 
hepatitis E virus. J Virol Methods. 2006; 
131:65–71. http://dx.doi.org/10.1016/j.j 
viromet.2005.07.004
  8.  Gilliland SM, Forrest L, Carre H, Jenkins 
A, Berry N, Martin J, et al. Investigation 
of porcine circovirus in human vaccines. 
Biologicals. 2012;40:270–7. http://dx.doi.
org/10.1016/j.biologicals.2012.02.002
  9.  Lau SKP, Woo PCY, Tse H, Fu CTY, Au 
Wk, Chen XC, et al. Identification of 
novel porcine and bovine parvoviruses 
closely related to human parvovirus 4. J 
Gen Virol. 2008;89:1840–8. http://dx.doi.
org/10.1099/vir.0.2008/000380-0
10.  Soucie JM, Erdman DD, Evatt BL, 
Anderson LJ, Torok TJ, El-Jamil M, 
et al. Investigation or porcine parvo-
virus among persons with hemophilia 
receiving Hyate:C porcine factor VIII 
concentrate. Transfusion. 2000;40: 
708–11. http://dx.doi.org/10.1046/j.1537-
2995.2000.40060708.x
Address for correspondence: H. Dalton, Royal 
Cornwall Hospital, Truro, UK; email: harry.
dalton@rcht.cornwall.nhs.uk
688	 Emerging	Infectious	Diseases	•	www.cdc.gov/eid	•	Vol.	19,	No.	4,	April	2013
